Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650767 · ClinicalTrials.gov registry record · Phase 2
A Study of ARRY-438162 in Patients With Rheumatoid Arthritis
A Phase 2 study, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
NCT00650767 is a Phase 2 study that has completed, run by Array Biopharma, now a wholly owned subsidiary of Pfizer. The registered enrollment target is 201 participants.
The verdict
NCT00650767, a Phase 2 study, has completed, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
Study Summary
This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-438162 in treating rheumatoid arthritis in patients on stable doses of methotrexate, and to further evaluate the safety of the study drug. Approximately 200 patients from the US, Argentina, Brazil, Hungary, Peru, Poland and Romania will be enrolled in this study.
Interventions
- DRUG Placebo; oral
- DRUG ARRY-438162, MEK inhibitor; oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650767
The ClinicalTrials.gov registry entry for NCT00650767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo; oral is the first listed.
NCT00650767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650767 about?
NCT00650767 is a clinical study titled "A Study of ARRY-438162 in Patients With Rheumatoid Arthritis". This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-438162 in treating rheumatoid arthritis in patients on stable doses of methotrexate, and to further evaluate the safety of the study drug. Approximately 200 patien...
What is the current status of trial NCT00650767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2008-03. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00650767?
The interventions under investigation include: Placebo; oral (DRUG), ARRY-438162, MEK inhibitor; oral (DRUG).
Who is sponsoring clinical trial NCT00650767?
This trial is sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.